UPB Stock Analysis: Buy, Sell, or Hold?
UPB - Upstream Bio, Inc. Common Stock
$9.51
0.22 (2.37%)
▲
5d:
+2.7%
30d:
+9.69%
90d:
-70.74%
BUY
HIGH Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 05, 2026
5d
Get Alerted When UPB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: UPB shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: UPB shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: UPB is currently trading at $9.51, which is considered fair relative to its 30-day fair value range of $9.01 to $10.12.
Technical Outlook: Technically, UPB is in a strong downtrend. Immediate support is located at $9.06, while resistance sits at $10.64.
Market Sentiment: UPB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $43.57 (+358.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, UPB is in a strong downtrend. Immediate support is located at $9.06, while resistance sits at $10.64.
Market Sentiment: UPB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $43.57 (+358.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.01 -
$10.12
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 358.2% below Wall St target ($43.57)
Trading Range Analysis
30-Day Trading Range
$9.01 -
$10.12
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.47
(15.5%)
Support & Resistance Levels
Support Level
$9.06
Resistance Level
$10.64
Current Trend
Strong Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.95
Wall Street Target
$43.57
(+358.2%)
Revenue Growth (YoY)
9.0%
Share & Embed Analysis
Last updated: April 29, 2026 8:46 AM ET
Data refreshes hourly during market hours. Next update: 9:46 AM
Data refreshes hourly during market hours. Next update: 9:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UPB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Gray
SELL
852 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 67 BUY |
